Citations to this article

Targeting secondary immune responses to cetuximab: CD137 and the outside story
Julie E. Bauman, Jennifer R. Grandis
Julie E. Bauman, Jennifer R. Grandis
Published May 16, 2014
Citation Information: J Clin Invest. 2014;124(6):2371-2375. https://doi.org/10.1172/JCI76264.
View: Text | PDF
Commentary Article has an altmetric score of 16

Targeting secondary immune responses to cetuximab: CD137 and the outside story

Abstract

Cetuximab is a murine-human chimeric IgG1 mAb directed against the EGFR that is approved for use in patients with colorectal and head and neck carcinomas. While some patients benefit greatly from cetuximab, many do not; therefore, strategies to increase the efficacy of this drug are of great clinical interest. In this issue of the JCI, Kohrt and colleagues report a strategy for enhancing the secondary immune response to cetuximab that involves sequential targeting with an agonist mAb against CD137 expressed on NK and T cells.

Authors

Julie E. Bauman, Jennifer R. Grandis

×

Total citations by year

Year: 2023 2017 Total
Citations: 1 4 5
Citation information

Citations to this article (5)

Title and authors Publication Year
Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression
Wei Z, Wang Z, Chai Q, Li Z, Zhang M, Zhang Y, Zhang L, Tang Q, Zhu H, Sui H 		Experimental and therapeutic medicine 2023
Strategies for Increasing Pancreatic Tumor Immunogenicity
BA Johnson, M Yarchoan, V Lee, DA Laheru, EM Jaffee 		Clinical cancer research 2017
Head and Neck Carcinoma Immunotherapy: Facts and Hopes
TL Whiteside 		Clinical cancer research 2017
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma
JD Moy, JM Moskovitz, RL Ferris 		European Journal of Cancer 2017
Radiotherapy plus EGFR inhibitors: synergistic modalities
P Bossi, F Platini 		Cancers of the Head & Neck 2017

Advertisement